Bloembergen W E, Stannard D C, Port F K, Wolfe R A, Pugh J A, Jones C A, Greer J W, Golper T A, Held P J
United States Renal Data System, University of Michigan, Ann Arbor, USA.
Kidney Int. 1996 Aug;50(2):557-65. doi: 10.1038/ki.1996.349.
A number of studies have found a relationship of lower all-cause mortality risk for ESRD patients treated with increasing dose of dialysis. The objective of this study was to determine the relationship of delivered dose of dialysis with cause-specific mortality. Data from the USRDS Case Mix Adequacy Study, which includes a national random sample of hemodialysis patients, were utilized. To minimize the contribution of unmeasured residual renal function, the sample used in this analysis (N = 2479) included only patients on dialysis for one year or more. Cox proportional hazards models, stratified for diabetes, were used to analyze the effect of delivered dose of dialysis (measured and reported by both Kt/V and URR) on major causes of death and withdrawal from dialysis, adjusting for other covariates including demographics, comorbid diseases present at start of study, functional status, laboratory values and other dialysis parameters. Patient follow-up for mortality was censored at the earliest of time of transplantation, 60 days after a switch to peritoneal dialysis or at the time of data abstraction. For each 0.1 higher Kt/V, the adjusted relative risk of death due to coronary artery disease was 9% lower (RR = 0.91, P < 0.05), due to other cardiac causes was 12% lower (RR = 0.88, P < 0.01), due to cerebrovascular disease (CVD) was 14% lower (RR = 0.86, P < 0.05), due to infection was 9% lower (RR = 0.91, P = 0.05), and due to other known causes was 6% lower (RR = 0.94, P < 0.05). There was no statistically significant relationship of Kt/V and risk of death among patients who died of malignancy (RR = 0.84, P = 0.10) or among patients whose death cause was missing (RR = 0.95, P = 0.41). The risk of withdrawal from dialysis prior to death due to any cause was 9% lower (RR = 0.91, P < 0.05) for each 0.1 higher Kt/V. The relationships of delivered dose of dialysis, as measured by URR, and cause-specific mortality were essentially similar in relative magnitude and statistical significance as the relationships observed using Kt/V as the measurement of dialysis dose, with the exception that the relationship was less significant for cerebrovascular disease and withdrawal from dialysis. The relationship of dialysis dose with risk of death due to each cause of death category except other cardiac causes and "other" causes appeared to be of greater magnitude and of greater statistical significance among diabetics than non-diabetics. These results indicate that low dose of dialysis is not associated with mortality due to just one isolated cause of death, but rather is due to a number of the major causes of death in this population. This study is consistent with hypotheses that low doses of dialysis may promote atherogenesis, infection, malnutrition and failure to thrive through a variety of pathophysiologic mechanisms. Further study is necessary to confirm these results and to test hypotheses that are developed.
多项研究发现,接受透析剂量增加治疗的终末期肾病(ESRD)患者全因死亡风险较低。本研究的目的是确定透析的实际剂量与特定病因死亡率之间的关系。我们使用了美国肾脏数据系统(USRDS)病例组合充分性研究的数据,该研究包括全国血液透析患者的随机样本。为了尽量减少未测量的残余肾功能的影响,本分析中使用的样本(N = 2479)仅包括透析一年或更长时间的患者。采用针对糖尿病分层的Cox比例风险模型,分析透析的实际剂量(通过Kt/V和尿素清除率(URR)测量和报告)对主要死亡原因和透析退出的影响,并对其他协变量进行调整,包括人口统计学、研究开始时存在的合并疾病、功能状态、实验室值和其他透析参数。患者的死亡随访在移植时间、转为腹膜透析后60天或数据提取时间三者中最早的时间进行截尾。Kt/V每升高0.1,因冠状动脉疾病死亡的校正相对风险降低9%(风险比(RR)= 0.91,P < 0.05),因其他心脏原因死亡的校正相对风险降低12%(RR = 0.88,P < 0.01),因脑血管疾病(CVD)死亡的校正相对风险降低14%(RR = 0.86,P < 0.05),因感染死亡的校正相对风险降低9%(RR = 0.91,P = 0.05),因其他已知原因死亡的校正相对风险降低6%(RR = 0.94,P < 0.05)。在死于恶性肿瘤的患者中(RR = 0.84,P = 0.10)或死亡原因不明的患者中(RR = 0.95,P = 0.41),Kt/V与死亡风险之间无统计学显著关系。Kt/V每升高0.1,因任何原因在死亡前退出透析的风险降低9%(RR = 0.91,P < 0.05)。以URR衡量的透析实际剂量与特定病因死亡率之间的关系,在相对大小和统计学意义上与使用Kt/V作为透析剂量测量值时观察到的关系基本相似,唯一的例外是脑血管疾病和透析退出的关系不太显著。除其他心脏原因和“其他”原因外,透析剂量与各死亡原因类别导致的死亡风险之间的关系在糖尿病患者中似乎比非糖尿病患者更大且具有更大的统计学意义。这些结果表明,低剂量透析并非仅与某一孤立死亡原因导致的死亡率相关,而是与该人群中的多种主要死亡原因相关。本研究与以下假设一致,即低剂量透析可能通过多种病理生理机制促进动脉粥样硬化、感染、营养不良和生长发育不良。有必要进一步研究以证实这些结果并检验所提出的假设。